User login
Key clinical point: The binary outcomes of atopic dermatitis (AD) were most effectively improved up to week 16 by 30 mg upadacitinib daily and 200 mg abrocitinib daily, followed by 15 mg upadacitinib daily, and 600 mg dupilumab and subsequently 300 mg dupilumab every 2 weeks.
Major finding: The odds of achieving 50% improvement in the Eczema Area and Severity Index scores were higher with daily doses of 200 mg abrocitinib (odds ratio [OR] 1.5, 95% credible interval [CrI] 1.1-2.2), 30 mg upadacitinib (OR 2.5, 95% CrI 1.3-5.0), and 15 mg upadacitinib (OR 1.7; 95% CrI 0.9-3.3) and lower with 100 mg abrocitinib daily (OR 0.7; 95% CrI 0.5-1.0) and 4 mg baricitinib daily (OR 0.5; 95% CrI 0.3-0.7) compared with dupilumab every 2 weeks.
Study details: This network meta-analysis of 83 trials included 22,122 patients with moderate-to-severe AD receiving systemic immunomodulatory treatment for ≥8 weeks.
Disclosures: This study was sponsored by a UK National Institute for Health Research Career Development Fellowship held by C Flohr and other funds. Seven authors declared ties with various sources.
Source: Drucker AM et al. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. Br J Dermatol. 2023 (Oct 13). doi: 10.1093/bjd/ljad393
Key clinical point: The binary outcomes of atopic dermatitis (AD) were most effectively improved up to week 16 by 30 mg upadacitinib daily and 200 mg abrocitinib daily, followed by 15 mg upadacitinib daily, and 600 mg dupilumab and subsequently 300 mg dupilumab every 2 weeks.
Major finding: The odds of achieving 50% improvement in the Eczema Area and Severity Index scores were higher with daily doses of 200 mg abrocitinib (odds ratio [OR] 1.5, 95% credible interval [CrI] 1.1-2.2), 30 mg upadacitinib (OR 2.5, 95% CrI 1.3-5.0), and 15 mg upadacitinib (OR 1.7; 95% CrI 0.9-3.3) and lower with 100 mg abrocitinib daily (OR 0.7; 95% CrI 0.5-1.0) and 4 mg baricitinib daily (OR 0.5; 95% CrI 0.3-0.7) compared with dupilumab every 2 weeks.
Study details: This network meta-analysis of 83 trials included 22,122 patients with moderate-to-severe AD receiving systemic immunomodulatory treatment for ≥8 weeks.
Disclosures: This study was sponsored by a UK National Institute for Health Research Career Development Fellowship held by C Flohr and other funds. Seven authors declared ties with various sources.
Source: Drucker AM et al. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. Br J Dermatol. 2023 (Oct 13). doi: 10.1093/bjd/ljad393
Key clinical point: The binary outcomes of atopic dermatitis (AD) were most effectively improved up to week 16 by 30 mg upadacitinib daily and 200 mg abrocitinib daily, followed by 15 mg upadacitinib daily, and 600 mg dupilumab and subsequently 300 mg dupilumab every 2 weeks.
Major finding: The odds of achieving 50% improvement in the Eczema Area and Severity Index scores were higher with daily doses of 200 mg abrocitinib (odds ratio [OR] 1.5, 95% credible interval [CrI] 1.1-2.2), 30 mg upadacitinib (OR 2.5, 95% CrI 1.3-5.0), and 15 mg upadacitinib (OR 1.7; 95% CrI 0.9-3.3) and lower with 100 mg abrocitinib daily (OR 0.7; 95% CrI 0.5-1.0) and 4 mg baricitinib daily (OR 0.5; 95% CrI 0.3-0.7) compared with dupilumab every 2 weeks.
Study details: This network meta-analysis of 83 trials included 22,122 patients with moderate-to-severe AD receiving systemic immunomodulatory treatment for ≥8 weeks.
Disclosures: This study was sponsored by a UK National Institute for Health Research Career Development Fellowship held by C Flohr and other funds. Seven authors declared ties with various sources.
Source: Drucker AM et al. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. Br J Dermatol. 2023 (Oct 13). doi: 10.1093/bjd/ljad393